SEP 19, 2017 02:59 PM PDT

Melatonin Could Ease Chemo Pains


Image credit:

A common over-the-counter drug that pilots often take to alleviate jetlag may also help cancer patients ease the pain from chemotherapy.

According to a new study from the University of Edinburg, the drug melatonin blocks the pain signals from chemo-damaged nerve cells in rats.

The findings were based on research on a common condition known as chemotherapy-induced neuropathic pain (CINP). Patients suffering from this condition often report tingling and sensitivity to hot and cold temperatures. It’s thought that the chemotherapy agents damage nerve cells, causing such painful sensations.

In animal studies, researchers found that melatonin had the best effect if given before chemotherapy. That is, if given prior to the start of chemotherapy, nerve damage is reduced. If given after CINP has already developed, melatonin seemed to be ineffective. This suggest that melatonin is more of a preventative therapy for CINP, rather than a curative one.  

"These results are promising, especially as melatonin treatment is known to be safe in other conditions. However, more work will need to be done before we know if melatonin will help prevent pain in cancer patients undergoing chemotherapy,” said Dr. Helen Galley, a professor at the Institute of Medical Sciences at the University of Aberdeen, and the study’s co-lead author. It’s not entirely clear how melatonin reduces nerve damage from chemotherapy.

Under normal conditions, the body produces melatonin at night to prepare us for rest and sleep. Synthetic version of melatonin also exist and function in a similar fashion. In the US, the drug is available over the counter, but in some other countries, a prescription is required.

"We are actively exploring an early-phase clinical study to see if these exciting laboratory findings might translate to direct benefit for patients undergoing chemotherapy. This is an area of real unmet need, where new therapies are urgently required,” said Dr. Lesley Colvin, a pain specialist at the University of Edinburgh, and a study co-author.

It’s estimated that CINP affects nearly 70 percent of cancer patients undergoing chemotherapy. The condition can worsen the quality of life for patients undergoing treatment. Furthermore, CINP can persist in some patients even after chemotherapy. As such, finding a drug that can reduce the occurrence of this condition would benefit patients and caregivers.

"CINP can have a devastating impact on patients, and may limit chemotherapy doses, with potentially serious consequences. These findings are very exciting and suggest that melatonin could prevent CINP by protecting nerve cell mitochondria. Our next steps will be to further test this theory by looking at the effect of melatonin in other pain conditions that also involve mitochondrial damage,” said Dr. Carole Torsney, the study’s co-leader.

Additional sources: University of Edinburg via Science Daily

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at
You May Also Like
DEC 14, 2018
DEC 14, 2018
CAR-T Cell Therapy 101
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a useful tool for cancer treatments in a small number of cancers thus far. This area of treatment research is expanding rapidl...
SEP 11, 2018
Cannabis Sciences
SEP 11, 2018
The Potential Anti-cancer Effects of Cannabinoids
They're known for helping to reduce the impact of cancer drug side effects, but it's possible that cannabinoids themselves are cancer fighters....
SEP 26, 2018
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 29, 2018
OCT 29, 2018
Escape of the Tumor Cell
Tumor cells in breast cancer have proven to evade the immune responses utilizing actin cytoskeleton...
OCT 31, 2018
OCT 31, 2018
Researchers identify a protein marker that induces dormancy in metastatic breast cancer
Researchers at the Mount Sinai hospital identified for the first time a protein marker that could indicate whether breast cancer will further metastasize or remains in a dormant state accordi...
FEB 16, 2019
Cell & Molecular Biology
FEB 16, 2019
Using Cellular Barcoding to Understand the Spread of Breast Cancer
Researchers have found that while chemotherapy can reduce the size of a tumor, it may not eliminate all of the cancerous cells....
Loading Comments...